Pregabalin
- Generic Name
- Pregabalin
- Brand Names
- Lyrica, Pregabalin Accord, Pregabalin Pfizer, Pregabalin Sandoz, Pregabalin Mylan, Pregabalin Zentiva
- Drug Type
- Small Molecule
- Chemical Formula
- C8H17NO2
- CAS Number
- 148553-50-8
- Unique Ingredient Identifier
- 55JG375S6M
- Background
Pregabalin is structurally similar to gamma-aminobutyric acid (GABA) - an inhibitory neurotransmitter. It may be used to manage neuropathic pain, postherpetic neuralgia, and fibromyalgia among other conditions. Although as per the FDA Label the mechanism of action has not been definitively defined, there is evidence that pregabalin exerts its effects by bind...
- Indication
Pregabalin is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, neuropathic pain associated with spinal cord injury, and as adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older.
- Associated Conditions
- Diabetic Peripheral Neuropathic Pain (DPN), Epilepsies, Fibromyalgia, Generalized Anxiety Disorder, Neuropathic Pain, Partial-Onset Seizures, Peripheral Neuropathic Pain, Peripheral neuropathy, Postherpetic Neuralgia
- Associated Therapies
- -
Pregabalin add-on for Neuropathic Pain in Cervical Myelopathy
- First Posted Date
- 2018-08-07
- Last Posted Date
- 2018-08-07
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT03618589
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Combination Effects of Pregabalin and Dexmedetomidine on Postoperative Pain
- Conditions
- Interventions
- First Posted Date
- 2018-05-01
- Last Posted Date
- 2018-05-01
- Lead Sponsor
- Wonkwang University Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT03512574
- Locations
- 🇰🇷
WonwangUH, Iksan, Jeonbuk, Korea, Republic of
MAST Trial: Multi-modal Analgesic Strategies in Trauma
- First Posted Date
- 2018-03-21
- Last Posted Date
- 2021-06-18
- Target Recruit Count
- 1561
- Registration Number
- NCT03472469
- Locations
- 🇺🇸
The University of Texas Health Science Center at Houston, Houston, Texas, United States
Pregabalin Stabilize Cardiovascular Response to Intubation
- Conditions
- Interventions
- First Posted Date
- 2018-03-07
- Last Posted Date
- 2018-03-09
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT03456947
Trial of Pregabalin for Granulocyte Colony-stimulating Factor (GCSF)-Induced Bone Pain
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2018-06-26
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT03407430
- Locations
- 🇺🇸
North Carolina Cancer Hospital, Chapel Hill, North Carolina, United States
Localized Neuropathic Pain: Topical Treatment Versus Systemic Treatment
- Conditions
- Interventions
- First Posted Date
- 2017-11-21
- Last Posted Date
- 2021-04-28
- Lead Sponsor
- University Hospital, Antwerp
- Target Recruit Count
- 33
- Registration Number
- NCT03348735
- Locations
- 🇧🇪
AZ Klina, Brasschaat, Belgium
🇧🇪UZ Brussel, Jette, Belgium
🇧🇪Hopital Universitaire Sart Tilman de Liège (ULg) (CHU), Liège, Belgium
Preoperative Oral Pregabalin Effect on Inhalational Anesthetic Requirements ln Hysterectomy Under General Anesthesia
- First Posted Date
- 2017-10-05
- Last Posted Date
- 2018-01-09
- Lead Sponsor
- Nesrine El-Refai
- Target Recruit Count
- 50
- Registration Number
- NCT03302208
- Locations
- 🇪🇬
Cairo University, Cairo, Zamalek, Egypt
Pregabalin Effects on Hypotensive Anesthesia During Spine Surgery.
- First Posted Date
- 2017-10-04
- Last Posted Date
- 2020-09-18
- Lead Sponsor
- Mansoura University
- Target Recruit Count
- 106
- Registration Number
- NCT03301025
- Locations
- 🇪🇬
Mansoura University Hospital, Mansourah, Dakahlia, Egypt
🇪🇬Delta Hospital, Mansourah,, Dakahlia, Egypt
Pregabalin as Treatment for Alcohol Use Disorder
- First Posted Date
- 2017-08-21
- Last Posted Date
- 2020-08-31
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 18
- Registration Number
- NCT03256253
- Locations
- 🇺🇸
Columbia Univeristy-STARS, New York, New York, United States
Clinical Trial to Evaluate the Efficacy and Safety of 'GLA5PR GLARS-NF1 Tab.' in Peripheral Neuropathic Pain
- Conditions
- Interventions
- First Posted Date
- 2017-07-19
- Last Posted Date
- 2019-03-19
- Lead Sponsor
- Daewon Pharmaceutical Co., Ltd.
- Target Recruit Count
- 352
- Registration Number
- NCT03221907
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.